Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

Phase 3

Recruiting

• Conditions: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
• Interventions: Drug: Pyridoxal Phosphate

• Registration Number: NCT04706013
• Lead Sponsor: Medicure

Brief Summary

The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-08
• Study First Submitted QC: 2021-01-11
• Study First Posted: 2021-01-12
• Study Start: 2024-02-16
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-28
• Last Update Posted: 2025-03-05
• Primary Completion: 2025-05
• Study Completion: 2025-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Patients with confirmed PNPO deficiency via genetic analysis, whose seizures are typically controlled on P5P (oral) therapy.

   a. Typically controlled is defined as receiving multiple doses of P5P daily to control seizures. Receiving P5P for a minimum of 30 days.

2. Male and/or female patients.

3. Patients with previous failed treatment on pyridoxine are eligible for the study (patient should be off pyridoxine for at least 24 hours).

4. Written informed consent (by parent or guardian if under the age of 18).

Exclusion Criteria

1. The patient has any condition or abnormality which may, in the opinion of the Investigator, compromise the safety of the patient, or influence their ability to comply with study procedures.
2. Known or suspected allergy to the trial drug or the relevant drugs given in the trial.
3. Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study. Participation in observational registry studies is permitted.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm Active	Pyridoxal Phosphate	Pyridoxal 5'-Phosphate

Primary Outcome Measures

Name	Time	Method
Overall survival time (time to death), including incidence of death at 12 months	12 months	The study group will be compared to a historical control group (without active treatment) for overall survival by using the method of survival analysis

Secondary Outcome Measures

Name	Time	Method
Frequency of seizures (including but not limited to status epilepticus)	up to 12 months	The frequency of seize will be compared between different treatment periods of the current single arm: Pharmaceutical grade oral P5P treatment period vs period prior to any P5P treatment (if data available)

Trial Locations

Locations (6)

Children's Hospital of Alabama; 🇺🇸 Birmingham, Alabama, United States

Lucile Packard Children's Hospital; 🇺🇸 Palo Alto, California, United States

Boston Children's Hospital; 🇺🇸 Boston, Massachusetts, United States

Duke Children's Hospital; 🇺🇸 Durham, North Carolina, United States

Akron's Children's Hospital; 🇺🇸 Akron, Ohio, United States

Queensland Children's Hospital; 🇦🇺 South Brisbane, Queensland, Australia